Acute Exposure to Apolipoprotein A1 Inhibits Macrophage Chemotaxis in Vitro and Monocyte Recruitment in Vivo

Overview

Journal Elife

Specialty Biology

Date 2016 Aug 31

PMID 27572261

Citations 39

Authors

Asif J Iqbal

Tessa J Barrett

Lewis Taylor

Eileen McNeill

Arun Manmadhan

Carlota Recio

Alfredo Carmineri

Maximillian H Brodermann

Gemma E White

Dianne Cooper

Joseph A DiDonato

Maryam Zamanian-Daryoush

Stanley L Hazen

Keith M Channon

David R Greaves

Edward A Fisher

Affiliations

Soon will be listed here.

Abstract

Apolipoprotein A1 (apoA1) is the major protein component of high-density lipoprotein (HDL) and has well documented anti-inflammatory properties. To better understand the cellular and molecular basis of the anti-inflammatory actions of apoA1, we explored the effect of acute human apoA1 exposure on the migratory capacity of monocyte-derived cells in vitro and in vivo. Acute (20-60 min) apoA1 treatment induced a substantial (50-90%) reduction in macrophage chemotaxis to a range of chemoattractants. This acute treatment was anti-inflammatory in vivo as shown by pre-treatment of monocytes prior to adoptive transfer into an on-going murine peritonitis model. We find that apoA1 rapidly disrupts membrane lipid rafts, and as a consequence, dampens the PI3K/Akt signalling pathway that coordinates reorganization of the actin cytoskeleton and cell migration. Our data strengthen the evidence base for therapeutic apoA1 infusions in situations where reduced monocyte recruitment to sites of inflammation could have beneficial outcomes.

Citing Articles

Monocytes to Apolipoprotein A1 ratio is associated with metabolic dysfunction-associated fatty liver disease in type 2 diabetes mellitus.

Wang W, Huang L, Qiu X, Tu M, Guo X Sci Rep. 2024; 14(1):31396.

PMID: 39733102 PMC: 11682227. DOI: 10.1038/s41598-024-82994-4.

The Interplay of Systemic Inflammation and Oxidative Stress in Connecting Perirenal Adipose Tissue to Hyperuricemia in Type 2 Diabetes Mellitus: A Mediation Analysis.

Wang W, Tu M, Qiu X, Tong Y, Guo X J Inflamm Res. 2024; 17:11319-11329.

PMID: 39720699 PMC: 11668320. DOI: 10.2147/JIR.S488964.

Prognostic Value of High-Density Lipoprotein Cholesterol in Patients with Overt Hepatic Encephalopathy.

Shi K, Bi Y, Wang X, Li Y, Zeng X, Feng Y Biomedicines. 2024; 12(8).

PMID: 39200247 PMC: 11351328. DOI: 10.3390/biomedicines12081783.

The Pleiotropic Effects of Lipid-Modifying Interventions: Exploring Traditional and Emerging Hypolipidemic Therapies.

Kounatidis D, Tentolouris N, Vallianou N, Mourouzis I, Karampela I, Stratigou T Metabolites. 2024; 14(7).

PMID: 39057711 PMC: 11278853. DOI: 10.3390/metabo14070388.

Gene Cluster at 11q23.3 and Lipid Metabolism Disorders: From Epigenetic Mechanisms to Clinical Practices.

Xiao Q, Wang J, Wang L, Ding H Biomedicines. 2024; 12(6).

PMID: 38927431 PMC: 11201263. DOI: 10.3390/biomedicines12061224.

References

Murphy A, Woollard K, Hoang A, Mukhamedova N, Stirzaker R, McCormick S . High-density lipoprotein reduces the human monocyte inflammatory response. Arterioscler Thromb Vasc Biol. 2008; 28(11):2071-7. DOI: 10.1161/ATVBAHA.108.168690. View

Vorotnikov A . Chemotaxis: movement, direction, control. Biochemistry (Mosc). 2012; 76(13):1528-55. DOI: 10.1134/S0006297911130104. View

Wang N, Silver D, Thiele C, Tall A . ATP-binding cassette transporter A1 (ABCA1) functions as a cholesterol efflux regulatory protein. J Biol Chem. 2001; 276(26):23742-7. DOI: 10.1074/jbc.M102348200. View

Hewing B, Parathath S, Barrett T, Chung W, Astudillo Y, Hamada T . Effects of native and myeloperoxidase-modified apolipoprotein a-I on reverse cholesterol transport and atherosclerosis in mice. Arterioscler Thromb Vasc Biol. 2014; 34(4):779-89. PMC: 3966977. DOI: 10.1161/ATVBAHA.113.303044. View

Chajek-Shaul T, Hayek T, Walsh A, Breslow J . Expression of the human apolipoprotein A-I gene in transgenic mice alters high density lipoprotein (HDL) particle size distribution and diminishes selective uptake of HDL cholesteryl esters. Proc Natl Acad Sci U S A. 1991; 88(15):6731-5. PMC: 52162. DOI: 10.1073/pnas.88.15.6731. View

Murphy A, Woollard K, Suhartoyo A, Stirzaker R, Shaw J, Sviridov D . Neutrophil activation is attenuated by high-density lipoprotein and apolipoprotein A-I in in vitro and in vivo models of inflammation. Arterioscler Thromb Vasc Biol. 2011; 31(6):1333-41. DOI: 10.1161/ATVBAHA.111.226258. View

White G, Iqbal A, Greaves D . CC chemokine receptors and chronic inflammation--therapeutic opportunities and pharmacological challenges. Pharmacol Rev. 2013; 65(1):47-89. DOI: 10.1124/pr.111.005074. View

Koseki M, Hirano K, Masuda D, Ikegami C, Tanaka M, Ota A . Increased lipid rafts and accelerated lipopolysaccharide-induced tumor necrosis factor-alpha secretion in Abca1-deficient macrophages. J Lipid Res. 2006; 48(2):299-306. DOI: 10.1194/jlr.M600428-JLR200. View

Bursill C, Castro M, Beattie D, Nakhla S, van der Vorst E, Heather A . High-density lipoproteins suppress chemokines and chemokine receptors in vitro and in vivo. Arterioscler Thromb Vasc Biol. 2010; 30(9):1773-8. DOI: 10.1161/ATVBAHA.110.211342. View

10.

Smythies L, White C, Maheshwari A, Palgunachari M, Anantharamaiah G, Chaddha M . Apolipoprotein A-I mimetic 4F alters the function of human monocyte-derived macrophages. Am J Physiol Cell Physiol. 2010; 298(6):C1538-48. PMC: 2889631. DOI: 10.1152/ajpcell.00467.2009. View

11.

Allen S, Crown S, Handel T . Chemokine: receptor structure, interactions, and antagonism. Annu Rev Immunol. 2007; 25:787-820. DOI: 10.1146/annurev.immunol.24.021605.090529. View

12.

van Gils J, Derby M, Fernandes L, Ramkhelawon B, Ray T, Rayner K . The neuroimmune guidance cue netrin-1 promotes atherosclerosis by inhibiting the emigration of macrophages from plaques. Nat Immunol. 2012; 13(2):136-43. PMC: 3262880. DOI: 10.1038/ni.2205. View

13.

Kingwell B, Chapman M, Kontush A, Miller N . HDL-targeted therapies: progress, failures and future. Nat Rev Drug Discov. 2014; 13(6):445-64. DOI: 10.1038/nrd4279. View

14.

Pagler T, Wang M, Mondal M, Murphy A, Westerterp M, Moore K . Deletion of ABCA1 and ABCG1 impairs macrophage migration because of increased Rac1 signaling. Circ Res. 2010; 108(2):194-200. PMC: 3097897. DOI: 10.1161/CIRCRESAHA.110.228619. View

15.

Zernecke A, Weber C . Chemokines in atherosclerosis: proceedings resumed. Arterioscler Thromb Vasc Biol. 2014; 34(4):742-50. DOI: 10.1161/ATVBAHA.113.301655. View

16.

White G, McNeill E, Christou I, Channon K, Greaves D . Site-directed mutagenesis of the CC chemokine binding protein 35K-Fc reveals residues essential for activity and mutations that increase the potency of CC chemokine blockade. Mol Pharmacol. 2011; 80(2):328-36. PMC: 5357053. DOI: 10.1124/mol.111.071985. View

17.

De Nardo D, Labzin L, Kono H, Seki R, Schmidt S, Beyer M . High-density lipoprotein mediates anti-inflammatory reprogramming of macrophages via the transcriptional regulator ATF3. Nat Immunol. 2013; 15(2):152-60. PMC: 4009731. DOI: 10.1038/ni.2784. View

18.

Huang Y, DiDonato J, Levison B, Schmitt D, Li L, Wu Y . An abundant dysfunctional apolipoprotein A1 in human atheroma. Nat Med. 2014; 20(2):193-203. PMC: 3923163. DOI: 10.1038/nm.3459. View

19.

Campbell I, Humphries M . Integrin structure, activation, and interactions. Cold Spring Harb Perspect Biol. 2011; 3(3). PMC: 3039929. DOI: 10.1101/cshperspect.a004994. View

20.

Charo I, Ransohoff R . The many roles of chemokines and chemokine receptors in inflammation. N Engl J Med. 2006; 354(6):610-21. DOI: 10.1056/NEJMra052723. View